Association of Nerve Growth Factor, Chemokine (C-C motif) Ligands and Immunoglobulin E with Pruritus in Cutaneous T-cell Lymphoma

Suga, Hiraku; Sugaya, Makoto; Miyagaki, Tomomitsu; Ohmatsu, Hanako; Fujita, Hideki; Kagami, Shinji; Asano, Yoshihide; Tada, Yayoi; Kadono, Takafumi; Sato, Shinichi

doi:10.2340/00015555-1428

Cited by 31 publications

(30 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar VAS values were reported by Wright et al (8). The observations confirm the reports of other authors, that pruritus is more severe in the late stages (33). The pruritus score was highest in a patient with erythroderma, which is consistent with other studies (12,15,16).…”

Section: Discussionsupporting

confidence: 93%

Il-31 Does not Correlate to Pruritus Related to Early Stage Cutaneous T-cell Lymphomas but is Involved in Pathogenesis of the Disease

Malek¹,

Gleń²,

Rębała³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

Mycosis fungoides (MF) and Sézary syndrome (SS) belong to the group of primary cutaneous T-cell lymphomas (CTCL). Regardless of the stage of the disease, patients with MF and SS can suffer from chronic pruritus. The aim of the study was to investigate the correlation between the interleukin 31 (IL-31) serum level, the degree of pruritus and CTCL severity; and to compare the frequency of IL-31 gene polymorphisms between patients and the control group, and between patients at different stages of the disease. Pruritus affected 67.7% of patients with MF and SS in our study. The IL-31 serum level was significantly higher in CTCL patients than in the control group but there were no positive correlation between IL-31 serum level and pruritus. A statistically significant difference in allele frequencies for IL-31 IVS2+12 gene polymorphisms between early and advanced stages was detected; GAG haplotype was more frequent and AGA was less frequent in stage IA patients compared with patients in the other stages of the disease.

show abstract

Section: Discussionsupporting

confidence: 93%

Il-31 Does not Correlate to Pruritus Related to Early Stage Cutaneous T-cell Lymphomas but is Involved in Pathogenesis of the Disease

Malek¹,

Gleń²,

Rębała³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…Serum VEGF‐A levels did not correlate with serum lactate dehydrogenase, soluble IL‐2 receptor and thymus and activation‐regulated chemokine levels, all of which are disease severity markers (data not shown), but significantly correlated with serum immunoglobulin E and NGF levels ( r = 0.44, P < 0.05 and r = 0.58, P < 0.05, respectively; Fig. a,b), both of which are associated with pruritus in MF/SS . In addition, serum VEGF‐A levels significantly correlated with itch intensity measured by a visual analog scale ( r = 0.37, P < 0.05; Fig.…”

Section: Case Reportmentioning

confidence: 90%

“…Expression of TSLP, NGF and IL‐31, which are pruritogenic molecules released by keratinocytes, is augmented in lesional skin of MF/SS . TSLP mRNA expression by HaCaT cells and NHEK was significantly elevated after administration of VEGF‐A (Fig.…”

Section: Case Reportmentioning

confidence: 93%

Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sézary syndrome

Sakamoto

Miyagaki

Kamijo

et al. 2017

The Journal of Dermatology

View full text Add to dashboard Cite

Angiogenesis is an important step to support progression of malignancies, including mycosis fungoides (MF) and Sézary syndrome (SS). Vascular endothelial growth factor (VEGF)‐A, a key player in angiogenesis, is secreted by tumor cells of MF/SS and its expression levels in lesional skin correlated with disease severity. In this study, we examined serum VEGF‐A levels in MF/SS patients. Serum VEGF‐A levels were elevated in patients with erythrodermic MF/SS and the levels decreased after treatment. Importantly, serum VEGF‐A levels positively correlated with markers for pruritus. We also found that VEGF‐A upregulated mRNA expression of thymic stromal lymphopoietin by keratinocytes. Taken together, our study suggests that VEGF‐A can promote progression and pruritus in MF/SS. Inhibition of VEGF‐A signaling can be a therapeutic strategy for patients with erythrodermic MF/SS.

show abstract

“…Interleukin-2 diphtheria toxin fusion protein (denileukin diftitox) was designed to target this receptor in patients(35). CCL26 was shown to correlate with the clinical itch burden in CTCL patients(36), while another potent T cell chemoatractant CCL18 has been consistently shown to be upregulated in MF and correlate with the types of skin lesions (i.e., patch vs. plaque vs. tumors)(37). As evident from this brief overview, molecular markers identified in our study have a direct clinical correlation to disease symptoms and treatment as reported in the literature.…”

Section: Discussionmentioning

confidence: 99%

The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL)

Litvinov

Netchiporouk

Cordeiro

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose While many Mycosis Fungoides (MF) patients presenting with stage I disease enjoy an indolent disease course and normal life expectancy, about 15-20% of them progress to higher stages, and most ultimately succumb to their disease. Currently, it's not possible to predict which patients will progress and which patients will have a stable disease. Previously, we conducted microarray analyses with RT-PCR validation of gene expression in biopsy specimens from 60 stage I-IV CTCL patients, identified three distinct clusters based upon transcription profile and correlated our molecular findings with 6 years of clinical follow up. Experimental Design We test by RT-PCR within our prediction model the expression of ∼240 genes that were previously reported to play an important role in CTCL carcinogenesis. We further extend the clinical follow up of our patients to 11 years. We compare the expression of selected genes between MF/Sézary Sydrome and benign inflammatory dermatoses that often mimic this cancer. Results Our findings demonstrate that 52 out of the ∼240 genes can be classified into cluster 1-3 expression patterns and such expression is consistent with their suggested biological roles. Moreover, we determined that 17 genes (CCL18, CCL26, FYB, T3JAM, MMP12, LEF1, LCK, ITK, GNLY, IL2RA, IL-26, IL-22, CCR4, GTSF1, SYCP1, STAT5A, TOX) are able to both identify patients who are at risk of progression and also distinguish MF/SS from benign mimickers. Conclusions This study, combined with other gene expression analyses, prepares the foundation for the development of personalized molecular approach towards diagnosis and treatment of CTCL.

show abstract

Association of Nerve Growth Factor, Chemokine (C-C motif) Ligands and Immunoglobulin E with Pruritus in Cutaneous T-cell Lymphoma

Cited by 31 publications

References 38 publications

Il-31 Does not Correlate to Pruritus Related to Early Stage Cutaneous T-cell Lymphomas but is Involved in Pathogenesis of the Disease

Il-31 Does not Correlate to Pruritus Related to Early Stage Cutaneous T-cell Lymphomas but is Involved in Pathogenesis of the Disease

Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sézary syndrome

The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL)

Contact Info

Product

Resources

About